Search for: "CEPHALON, INC" Results 61 - 80 of 115
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 Dec 2008, 6:36 am by fraudfighters
In addition to the $425 million Cephalon settlement detailed in a November 14 post to this blog, the report listed a number of others cases that resulted in significant monetary awards. [read post]
11 Nov 2011, 2:00 am by Jack Pringle
Cephalon, Inc., Plaintiffs in a putative class action alleging violations of the Sherman Antitrust Act sought to compel discovery of certain communications between Defendant Barr Laboratories, Inc. [read post]
23 Mar 2007, 11:35 am
., Beckman Coulter, Bridgestone Americas, Bristol-Myers Squibb, Cargill Incorporated, Caterpillar, Cephalon, CheckFree, Corning, Dow Chemical, Eastman Chemical, Electronics for Imaging, E.I. du Pont (DuPont), Eli Lilly, ExxonMobil, General Electric, Genzyme, GlaxoSmithKline, Henkel Corporation, Hoffman-La Roche, Johnson & Johnson, Merck, Millennium Pharmaceuticals, Monsanto, Motorola, Novartis, Patent Café.com Inc., Pfizer, Procter &… [read post]
1 Apr 2015, 11:51 am by Montgomery McCracken
On March 23, 2015, the United States District Court for the Eastern District of Pennsylvania denied certification of a nationwide class of third party payors (“TPPs”) asserting unjust enrichment claims against Cephalon, Inc. [read post]
1 Jul 2008, 4:31 am
In previous reports, we noted that a handful of biotech/pharma companies spent significant amounts of money lobbying the federal government in the first quarter of 2008, including: • Abbott Laboratories -- $880,000 • Amgen Inc. -- $2.5 million • Cephalon,... [read post]
15 May 2018, 8:09 pm by Kurt R. Karst
Hull — Last week, the Superior Court of Pennsylvania struck a blow to Appellant Joseph Caltagirone’s wrongful death and survival claims against drug manufacturers Cephalon, Inc. and Teva Pharmaceuticals, USA, Inc. [read post]
31 Mar 2010, 2:37 am
FTC's Pay for Delay Case Against Cephalon Moves Forward "The Federal Trade Commission's crusade against "Pay for Delay" patent settlements between brand name and generic drug makers got a boost yesterday when a district court judge refused to dismiss a 2008 antitrust suit against Cephalon Inc."   [read post]